Company

Ionis Pharmaceuticals, Inc.

Headquarters: Carlsbad, CA, United States

Founded: 1989

Employees: 660

CEO: Dr. Brett P. Monia Ph.D.

NASDAQ: IONS +0.32%

Market Cap

$7.51 Billion

USD as of Jan. 1, 2024

history Market Cap History

Ionis Pharmaceuticals, Inc. market capitalization over time

Evolution of Ionis Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Ionis Pharmaceuticals, Inc.

Detailed Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

🐷

"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

Ionis Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IONS wb_incandescent

Stock: FSX: ISI wb_incandescent

Product & Services

nusinersen, inotersen, volanesorsen, plazomicin, mipomersen

Key People

Founder(s): Stanley T. Crooke

Brett P. Monia, CEO Elizabeth L. Hougen, CFO Joseph Loscalzo, Chairman of the Board

Financials

Revenue: $1.122 billion (2019)

Net income: $294 million (2019)


Total assets: $3.233 billion (2019)

Total equity: $1.684 billion (2019)

Details

Headquarters:

2855 Gazelle Court

Carlsbad, CA 92010

United States

Phone: 760 931 9200